Silymarin inhibits CYP3A4 in vitro; clinical significance debated
In vitro inhibition; may increase warfarin levels
Silymarin inhibits glucuronidation; may affect drug clearance
Case report of increased sirolimus levels
Silymarin may enhance metformin's effects on blood sugar
Both metabolized via CYP3A4; potential for increased statin levels
Not Prohibited
Zhong S et al. The therapeutic effect of silymarin in NAFLD: a meta-analysis.
Abenavoli L et al. Milk thistle in liver diseases: past, present, future.
Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome.
Voroneanu L et al. Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Independently graded against 173,636 indexed supplements with 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, and NIH DSLD | Last updated: April 2026
Not medical advice. Based on published clinical research and systematic reviews.